



Clinical Trial for NSCLC

Genentech ATLAS/AVF3752g

A Phase II Trial of Bevacizumab in Combination with First or Second Line Therapy in Subjects with Treated Brain Metastases Due to Non-Squamous NSCLC

Inclusion Criteria:

- Signed Informed Consent
- Histologically or cytologically confirmed NSCLC **except** for squamous cell carcinoma
 - Mixed tumors will be categorized by the predominant cell type unless small cell elements are present, in which case the patient is ineligible.
 - Sputum cytology alone is not acceptable.
- Treated brain metastases without evidence of progression or hemorrhage after treatment, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period (Day -28 to study enrollment)
 - Treatment for metastatic disease may include WBRT, RS (Gamma Knife, LINAC, or equivalent), or a combination as deemed appropriate by the treating physician
- Appropriateness for first or second line systemic therapy for advanced NSCLC
- ECOG performance status of 0 or 1
- Age \geq 18 years old
- Patient must be willing to use acceptable forms of birth control prior to study entry and for the duration of the study.